
Pfizer presented a takeover bid to ratiopharm that includes a plan to expand the generic drugmaker's production facilities and enlarge its sales network, according
to people familiar with the matter.
Speaking to a group of managers at ratiopharm, Pfizer CEO Jeff Kindler reportedly described ratiopharm's production efficiency as "best in class," according to one person,
who also said Kindler further expressed interest in ratiopharm's biotechnology operations.
In addition, sources said ratiopharm has met with Teva to discuss its takeover plan, while Actavis may present its bid shortly. Ratiopharm is expected to select a buyer by the end of the month

Commenting on the news, UniCredit analyst Silke Stegemann said that "big pharma is trying to build a generic pillar and ratiopharm would be exactly that for Pfizer." Recent market speculation suggested that Pfizer could bid as much as 3 billion euros ($4.1 billion) for the German drugmaker.
